drugset / Trial / NCT02405377

Central Venous Pressure Guided Hydration Prevention for Contrast-Induced Nephropathy

NCT02405377

Completed 264 enrolled Chinese PLA General Hospital
RandomizedParallel-groupTriple-blindPrevention

Summary

Patients at moderate and high risk for contrast induced nephropathy (CIN) should receive sufficient hydration before application of contrast to prevent CIN, but hydration could obviously increase the preload for congestive heart failure (CHF) patients. It is important to make an individual hydration protocol for patients with dysfunction of heart and renal to reduce the incidence rate of CIN. This prospective, randomized, double-blind, comparative clinical trial randomly selected 264 patients with estimated glomerular filtration rate, (eGFR) \<60 ml/min per 1.73 m2 and CHF undergoing coronary angiography to receive either the convention hydration (n=132) or the central venous pressure (CVP) guided hydration (n=132).

Timeline

Start
2014-02
Primary completion
2015-02
Completion
2015-02

Publications

Drugs

EvaluationDrugModalityDoseRoute
Background Iodixanol Diagnostic / imaging agent 320 mg/ml Other
Background sodium chloride Unknown 0.9 % Intravenous

Indications